Cassava Sciences stock price forecast for Q3 after shares rally 27% | Invezz
Invezz is an independent platform with the goal of helping users achieve financial freedom. In order to fund our work, we partner with advertisers who compensate us for users that Invezz refers to their services. While our reviews and assessments of each product on the site are independent and unbiased, brands may pay to appear higher up our table rankings or place ads in specific areas of the site. The order in which products and services appear on Invezz does not represent an endorsement from us, and please be aware that there may be other platforms available to you than the products and services that appear on our website. Read more about how we make money >
Jul 21, 2021
- Meme stock Cassava Sciences rallied 27% on Wednesday as it prepares to unveil its Alzheimer’s drug data.
- The Austin, TX-based biotech company will have a readout of its Alzheimer’s candidate Simufilam on 29th July.
- The SAVA stock price is up 1,532% this year and 3,283% over the last 12 months. Time to buy or sell?
Meme stock Cassava Sciences Inc. (NASDAQ:SAVA) shares surged more than 27% on Wednesday after revealing plans to present data on its Alzheimer’s drug, Simufilam, on 29th July.
Cassava will read out its interim analysis on a 9-month treatment with Simulflam at the 2021 Alzheimer’s Association International Conference (AAIC) in Denver. It will cover safety and cognition data from the first 50 patients with Alzheimer’s to complete the open-label treatment.
Are you looking for fast-news, hot-tips and market analysis?
Sign-up for the Invezz newsletter, today.
Cassava said the presentation would also include data from 25 patients who completed the 6-month cerebrospinal fluid (CSF) treatment.
Should you buy or sell Cassava shares now?
Cassava Sciences’ stock price spiked more than 1,500% this year after the FDA approved Biogen Inc.’s (NASDAQ:BIIB) Alzheimer’s drug Aduhelm. However, lately, Alzheimer’s drug developers have come under pressure after the US food and drug administration watchdog launched an investigation into Aduhelm amid questions about the approval process.
The SAVA stock price pulled back about 25% earlier this month before gaining nearly 43% this week. This week’s rebound appears to be driven by high expectations on the upcoming data readout.
SAVA shares appear to respond to market sentiment ahead or after a major event about the Alzheimer’s drug market. However, there is nothing concrete to bet on until Simufilam reaches the final stages of the approval process. As such, given Wednesday’s sharp spike, it could be best to take profits now before a pullback.
Technical overview: Cassava Sciences’ stock price predictions for Q3 2021
Technically, Cassava Sciences shares appear to have recently popped closer to overbought conditions in the 14-day RSI. Wednesday’s spike pushed SAVA shares to new all-time highs of about $121 before pulling back late on to $115.48.
Investors can target extended pullbacks at approximately $108.28 or lower at $101.09. The key resistance levels are $121.20 and $128.03.
Bottom line: the case for selling SAVA shares now
Although Wednesday’s spike will likely attract more investors to SAVA, the company is far from turning profits. In addition, analysts expect Cassava sciences loss to ballon 1000% next year. Therefore, Wednesday’s rebound is an opportunity to take profits or initiate a short position for traders.
Where to buy right now
To invest simply and easily, users need a low-fee broker with a track record of reliability. The following brokers are highly rated, recognised worldwide, and safe to use:
Health & pharmaceuticals
Stocks & Shares